Biotech Stocks

A Treatment That Improves The Condition Of MS Patients Could Improve The Condition Of This Beaten-Up Biotech

Ashley Hayes

Published on: 16/09/2019

Last year, this biotech firm had a $50 stock and $3 billion market cap. Today, it has a stock trading below $16 and a market cap of just $870 million. But it

Biotech InvestmentsCheap Biotech StocksMarket CapMS TreatmentStock MarketHealth StocksInvestInvestingInvestorsProfitable InvestmentsProfitable StocksStock Market

The New Paradigm For Biotech Investing

Ashley Hayes

Published on: 03/09/2018

There are very few diseases for which actual cures have been developed – but that could soon start to change. And with a “golden age of medicine” potentially

Biotech InvestingBiotech StocksGolden Age of MedicineInvestInvestingInvestmentMarketNew Biotech ParadigmStock MarketInvestingPerforming StocksProfitable InvestmentsProfitable StocksStock MarketStocks to Watch

Bargain Bin & Analyst Adored

Ashley Hayes

Published on: 29/06/2018

These three stocks – including a clinical-stage biotech with a still-promising drug candidate – may be under-performing at the moment, but some of Wall

Bargain Bin StocksBiotech StocksInvestingInvestment StrategyInvestmentsInvestorMarketMarket AnalystStock MarketStock PortfolioUnder Performing StocksWall StreetHealth StocksInvestingStock MarketStocks to Watch